Armata Pharmaceuticals Inc (A:ARMP)

Business Focus: Biotechnology & Medical Research

Mar 30, 2020 07:30 am ET
Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.
MARINA DEL REY, Calif., March 30, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that, following a vote in favor of the transaction by more than 99% of the Armata shareholders that voted, Armata has completed the closing of the second tranche under the Company's $25 million Securities Purchase Agreement with Innoviva, Inc. (NASDAQ: INVA) ("Innoviva"), a company with a portfolio of royalties that include res...
Mar 19, 2020 04:05 pm ET
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update
MARINA DEL REY, Calif., March 19, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the fourth quarter and full year 2019 and provided a corporate and clinical update.  ...
Mar 18, 2020 08:00 am ET
Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation
MARINA DEL REY, Calif., March 18, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has been awarded up to $5 million in a therapeutic development award from the Cystic Fibrosis Foundation (CFF). The award will help fund a Phase 1/2 clinical trial of the company's Pseudomonas aeruginosa phage candidate, AP-PA02, as a treatment for Pseudomonas airway infections in people with cystic fibrosis (CF). Armata plans ...
Nov 12, 2019 03:05 pm ET
Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update
MARINA DEL REY, Calif., Nov. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced third quarter results and provided a corporate and clinical update.  ...
Oct 31, 2019 07:05 am ET
Armata Pharmaceuticals Issues Letter to Shareholders
MARINA DEL REY, Calif., Oct. 31, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today issued the following letter to shareholders. The letter has been made available to all existing shareholders with the Proxy for the 2019 Armata Annual General Shareholders meeting to be held on December 10, 2019....
Oct 21, 2019 07:05 am ET
Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive
MARINA DEL REY, Calif., Oct. 21, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of USD $1.3 million from the Australian Tax Office based on Armata's R&D spending in Australia during 2018. Armata will recognize the $1.3 million payment received in its financial statements for the quarter ending December 31, 2019....
Oct 16, 2019 07:05 am ET
Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director
MARINA DEL REY, Calif., Oct. 16, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the appointment of Heather Dale Jones, M.D. as its first Medical Director, further strengthening Armata's clinical team as the company prepares to initiate clinical testing of its lead bacteriophage product candidates. Dr. Jones brings to the Armata team more than 20 years of experience in clinical research and medical practice....
Oct 10, 2019 04:05 pm ET
Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D.
MARINA DEL REY, Calif., Oct. 10, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has expanded its Board of Directors with the appointment of Todd C. Peterson, Ph.D. Dr. Peterson brings to the Armata Board more than 35 years of experience in biotechnology and life sciences research and development across the areas of molecular biology, nucleic acids and genomics product and technology development....
Sep 19, 2019 07:05 am ET
Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference
MARINA DEL REY, Calif., Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that management will be participating in the Ladenburg Thalmann 2019 Healthcare Conference, which is being held September 24 in New York. Management is scheduled to present at 3:30-4:00p ET....
Sep 12, 2019 09:00 am ET
Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the "Company" or "Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa (also referred to herein as "Pseudomonas" or "P. aeruginosa") to treat serious respiratory infections, with an emphasis on cystic fibrosis patients. The candidate, known as AP-PA02, is being developed as a...
Aug 14, 2019 04:05 pm ET
Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
MARINA DEL REY, Calif., Aug. 14, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced second quarter results and provided a corporate and clinical update.  ...
Aug 01, 2019 10:30 am ET
Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference
MARINA DEL REY, Calif., Aug. 1, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that Brian Varnum, PhD, President and Chief Development Officer, will present a corporate overview and host investor meetings at the Canaccord Genuity 39th Annual Growth Conference, being held August 7-8, 2019 at the InterContinental Boston Hotel.  ...
May 28, 2019 07:01 am ET
Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient
MARINA DEL REY, Calif, May 28, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with the Company's natural phage product, AP-PA01. The paper, entitled "Successful adjunctive use of bacteriophage therapy for treatment of multidrug‑resistant Pseudomonas aeruginosa infect...
May 09, 2019 04:01 pm ET
C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.
MARINA DEL REY, Calif., May 9, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the previously-announced merger between C3J Therapeutics, Inc. ("C3J") and AmpliPhi Biosciences Corporation ("AmpliPhi") has closed. The new combined company, known as Armata Pharmaceuticals, Inc., will focus on the development and advancement of phage-based therapeutic candidates to treat antibiotic-resistant infections. Armat...